1. Generics Bulletin
  2. >>Archive

Strides plans for US growth

Earlier this year, Strides Pharma Science outlined plans to adopt a “recalibrated strategy” in the US, with a focus on launches through its own commercial front-end rather than through partners. As well as pledging to take up a “front-end bias” in the country, Strides had also said it would exit its partnership business and eschew new “partnership contracts” (Generics bulletin, 25 May 2018, page 5).

Earlier this year, Strides Pharma Science outlined plans to adopt a “recalibrated strategy” in the US, with a focus on launches through its own commercial front-end rather than through partners. As well as pledging to take up a “front-end bias” in the country, Strides had also said it would exit its partnership business and eschew new “partnership contracts” (Generics bulletin, 25 May 2018, page 5).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Generics Bulletin

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Glenmark’s UK Dapagliflozin Blocked On Appeal After Teva Readied Launch

 
• By Dean Rudge

Glenmark’s advantage for its UK generic version of AstraZeneca’s Forxiga (dapagliflozin) has quickly been snuffed out, after the originator won on appeal its request for injunctive relief.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.